Skip to content
DataLookout
Menu

FLOURISHNCT07588984

GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study

StatusRecruiting
PhaseNot specified
SponsorNoom Inc.
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 6 more changesShow less
    • Eligibility criteria expanded, about 35 words
    • Enrollment increased: 2310 → 2541 participants
    • Start date changed from estimate of Apr 30, 2026 to May 26, 2026
    • Secondary endpoints: 6 to 9
    • Site details revised
    • Study description expanded, about 2 words
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Change in Body Weight
Timeframe: Monthly, Baseline through Month 12 (and Months 18 & 24 for FLOURISH GLP-1 arms)
Change in fasting glucose
Timeframe: Baseline, Month 2, Month 4, Month 8, Month 12
Change in HbA1c
Timeframe: Baseline, Month 2, Month 4, Month 8, Month 12
Change in LDL cholesterol
Timeframe: Baseline, Month 2, Month 4, Month 8, Month 12
Change in HDL cholesterol
Timeframe: Baseline, Month 2, Month 4, Month 8, Month 12
Change in total cholesterol
Timeframe: Baseline, Month 2, Month 4, Month 8, Month 12
Change in triglycerides
Timeframe: Baseline, Month 2, Month 4, Month 8, Month 12
Change in Body Composition
Timeframe: Monthly, Baseline through Month 12 ((and Months 18 & 24 for FLOURISH GLP-1 arms)
GLP-1 Side Effect Profile
Timeframe: Baseline (pre-treatment), Monthly through Month 12

Secondary (9)

Change in heart rate variability (HRV)
Change in resting heart rate (RHR)
Change in sleep duration
Change in time spent in sleep stages
Change in sleep continuity
Show 4 moreShow less
Sleep quality
Physical activity duration
Active calories burned
Stress score

Arms and interventions

Education only (control)

Arm 1 of FLOURISH: This is an active control condition in which participants will receive weekly informational newsletters for 12 months. This group will not have access to the Noom app (except for research purposes) and will not receive GLP-1 medications.

Noom Weight

Arm 2 of FLOURISH: Noom Weight users will have access to all in-app features. This group will not receive GLP-1 medications. Followed for 12 months.

Standard GLP-1Rx

Arm 3 of FLOURISH: Standard GLP-1 users will follow a protocol for Noom's standard dose of compounded semaglutide and will have access to all in-app features. Followed for up to 12 months of program with 18 and 24 month follow-up post-GLP-1 discontinuation.

Microdose GLP-1Rx

Arm 4 of FLOURISH: Microdose GLP-1 users will follow a microdose protocol of compounded semaglutide and will have access to all in-app features. Followed for up to 12 months of program with 18 and 24 month follow-up post-GLP-1 discontinuation.

Noom Plus

Arm 5 of FLOURISH: Participants will follow a protocol for Noom's standard dose of compounded tirzepatide and will have access to all in-app features. Followed for up to 12 months of program with 18 and 24 month follow-up post-GLP-1 discontinuation.

Noom Plus Microdose

Arm 6 of FLOURISH: Noom Plus Microdose users will follow a microdose protocol for compounded tirzepatide and will have access to all in-app features. Followed for up to 12 months of program with 18 and 24 month follow-up post-GLP-1 discontinuation.

Noom Free Tier (control)

Arm 1 of THRIVE: This is an active control condition in which users enrolled in Noom's Free Tier program will have access to app features available to Free Tier. This group will not receive GLP-1 medications. Followed for 12 months.

Proactive Health

Arm 2 of THRIVE: Proactive health users will follow the microdose protocol for compounded semaglutide indicated for preventive health/longevity. They will have access to all in-app features. Followed for 12 months.

Behavioral: Noom Weight, Free Tier, Education-only control

Drugs: Semaglutide, Tirzepatide, Microdose semaglutide, Microdose tirzepatide

Sites

1 site in 1 country

  • Noom, Inc.Princeton, New Jersey, United States